KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2025)

Ginkgo Bioworks Holdings' Cash from Operations history spans 6 years, with the latest figure at 47678000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 12.36% year-over-year to 47678000.0; the TTM value through Dec 2025 reached 171059000.0, up 46.47%, while the annual FY2025 figure was 171059000.0, 46.47% up from the prior year.
  • Cash from Operations reached 47678000.0 in Q4 2025 per DNA's latest filing, down from 31606000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5235000.0 in Q3 2021 to a low of 165541000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 64608000.0, with a median of 54676000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 441.76% in 2022, then soared 69.46% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 165541000.0 in 2021, then skyrocketed by 36.85% to 104531000.0 in 2022, then surged by 44.68% to 57831000.0 in 2023, then rose by 26.62% to 42435000.0 in 2024, then decreased by 12.36% to 47678000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNA's Cash from Operations are 47678000.0 (Q4 2025), 31606000.0 (Q3 2025), and 40254000.0 (Q2 2025).